Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report)'s share price dropped 5.9% during mid-day trading on Monday . The stock traded as low as $13.75 and last traded at $14.02. Approximately 49,062 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 202,594 shares. The stock had previously closed at $14.90.
Analysts Set New Price Targets
MAZE has been the subject of several research reports. Wedbush initiated coverage on shares of Maze Therapeutics in a research report on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 price objective for the company. HC Wainwright initiated coverage on shares of Maze Therapeutics in a research report on Wednesday, July 23rd. They issued a "buy" rating and a $34.00 price target for the company. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $25.60.
View Our Latest Stock Analysis on MAZE
Maze Therapeutics Trading Down 0.4%
The firm has a 50-day moving average of $13.84.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.39).
Institutional Investors Weigh In On Maze Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Alphabet Inc. acquired a new stake in shares of Maze Therapeutics in the first quarter worth $26,561,000. Bank of New York Mellon Corp purchased a new position in Maze Therapeutics in the first quarter worth approximately $190,000. General Catalyst Group Management LLC purchased a new stake in shares of Maze Therapeutics during the 1st quarter worth approximately $11,405,000. Bessemer Group Inc. acquired a new position in shares of Maze Therapeutics in the 1st quarter valued at $5,305,000. Finally, TRV GP V LLC acquired a new position in Maze Therapeutics in the 1st quarter valued at $10,468,000.
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
See Also
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access